Jeanine Sol et al. investigated sixty-one preterm and term neonates with 64 venous thromboembolisms, where fifty percent (32/64) reached TTR and the median nadroparin dosage required to reach TTR was found to be 197 (97.9–330.3) IU/kg q12 h (Sol et al., 2021). The gene discussed is TTR; the disease is venous thromboembolism.